Sulpiride treatment improved both the abnormal asymmetric saccadic eye movements (SEM) and the abnormal involuntary movements (AIMs) in a patient with Huntington's disease (HD). However, sulpiride corrected the abnormalities of SEM in the right, but not the left, hemi-field and the degeneration of the left striatal tissue was greater as visualised by the magnetic resonance imaging (MRI) scan.
Bird E.D. (1980) Chemical pathology of Huntington's disease. Annu Rev Pharmacol Toxicol20: 533-551
2.
Bird E.D., Iversen L.L. (1974) Huntington's chorea: postmortem measurement of glutamic acid decarboxylase, choline acetyl-transferase and dopamine in basal ganglia. Brain97: 457-472
3.
Dursun S.M., Andrews H., Reveley M.A. (1994) Computerised continuous assessment of abnormal involuntary movements in Huntington's disease; improvement by sulpiride. Br J Clin Pharmacol37: 503P-504P
4.
Knowling M.R., Wrench W. (1991) Treatment of Huntington's Chorea with sulpiride . SA Med J79: 169
5.
Lasker A.G., Zee D.S., Hain T.C., Folstein S.E., Singer H.S. (1988) Saccades in Huntington's disease, slowing and dysmetria . Neurology38: 427-431
6.
Melamed E., Hefti F., Bird E.D. (1982) Huntington's chorea is not associated with hyperactivity of nigrostriatal dopaminergic neurons: studies in postmortem tissues and in rats with kainic acid lesions. Neurology32: 640-644
7.
Morris M. (1991) Psychiatric aspects of Huntington's disease. In Harper P S (ed.) Huntington's disease. Saunders, London, pp. 81-126
8.
National Institute of Mental Health, Abnormal Involuntary Movement Scale (AIMs) (1976) In Guy O O (ed.), ECDEU assessment manual for psychopharmacology . U.S. Dept. of Health, Education, and WelfareRockville, MD, p. 534
9.
Quarrell O. (1991) The neurobiology of Huntington's disease. In Harper P S (ed.), Huntington's disease. Saunders, London, pp. 141-178
10.
Quarrell O., Harper P.S. (1991) The clinical neurology of Huntington's disease . In Harper P S (ed.), Huntington's disease. Saunders, London, pp. 37-80
11.
Quinn N., Marsden C.D. (1984) A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol, Neurosurg Psychiatr47: 844-847
12.
Spokes E G S (1979) Brain dopamine in Huntington's disease: a study of post-mortem tissue. Adv Neurol23: 481-493
13.
The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell72: 971-983
14.
Tryon W.W. (1991) Activity measurement in psychology and medicine . Plenum Press, New York, pp. 23-64
